Key points
- China has approved several commercial CAR-T products for certain blood cancers since 2021 and runs many clinical trials.
- A course means weeks in the country, often months, with close monitoring for serious side effects and a full-time carer.
- An approved product and a clinical trial are different things. Ask which one you are being offered.
China offers both, and the first thing to settle is which one you are being offered. China’s medicines regulator, the National Medical Products Administration, has approved several commercial CAR-T products since 2021, each for specific conditions and stages of disease. China also has a large number of registered CAR-T clinical trials. An approved product has passed regulatory review for a defined use; its manufacture is controlled, and there is published evidence on its effects and its risks. A trial is an experiment.
China is a serious place to consider for CAR-T, with approved products and experienced centres. It is also a field in which hope is easily sold, and much of what overseas patients have read about it was written by agencies with something to sell. Whether CAR-T suits any individual is a question for that person’s own specialists and the treating centre.
What the treatment involves
CAR-T stands for chimeric antigen receptor T-cell therapy, and it is made from the patient’s own immune cells. T cells, a type of white blood cell, are collected from the blood by a procedure resembling a long blood donation. In a laboratory they are genetically modified to carry a receptor that recognises a marker on the cancer cells, then multiplied, which usually takes some weeks. The patient receives a short course of chemotherapy to make room for the new cells. The modified cells are then given back through a drip, usually in a single session, and the patient is watched closely, in hospital and then nearby, for side effects and for response.
Commercially approved CAR-T products are used for certain blood cancers, including some lymphomas, some leukaemias and multiple myeloma. They are generally given after other treatments have failed or the disease has returned. In solid tumours and in other diseases, CAR-T is, at the time of writing, largely a matter of research.
CAR-T does not work for every patient, and responses do not always last. No centre can promise a result. Be wary of anyone who does.
Trials vary, and so does your standing in one
Some trials are company-sponsored studies designed to support an application for approval. Others are smaller, early-phase studies begun by hospital investigators. In a trial the treatment may be at an early stage, with little known about how well it works or how safe it is. Whether foreign nationals may enrol depends on the trial’s rules. Taking part can be reasonable, but it is research, and you should see the consent documents in a language you read well.
The list of approved products changes, so check the current position with the treating hospital. An agency that describes an experimental treatment as established has given you a warning sign; our guide to choosing a medical-travel agency suggests how to check such claims.
Cost and time are larger than the product
CAR-T in China can cost less than in the United States or Europe, sometimes considerably less. We quote no figures here, because they depend on the product, the hospital and the course of the illness, and they change. Two reasons are usually given: products developed and made in China are priced for the Chinese market, and hospital stays, staff time and supporting care cost less.
The product is one line on the bill. Hospital care before and after infusion, intensive care if it is needed, medicines, and several weeks of accommodation for two people all add to it. A complication can lengthen the stay and raise the cost substantially.
Plan for weeks in the country, often months. Assessment, cell collection, manufacture, preparation, infusion and monitoring follow one another, and none can be hurried. After infusion, patients are usually kept in hospital and then asked to remain within easy reach of the centre for some weeks. The best-known serious side effect is cytokine release syndrome, an inflammatory reaction that can cause high fever and low blood pressure. Effects on the nervous system, such as confusion or difficulty speaking, also occur. Both can be severe and may need intensive care, and low blood counts and infections can occur for months afterwards.
Centres generally require an adult companion to stay with the patient throughout, because the patient may be unable to recognise or report symptoms. Short visa-free entry will not cover a treatment of this length; see our guide to the China visa for medical travel. Monitoring continues for a long time after you return, so consult your haematologist or oncologist at home before you travel, and ask the centre for its own timetable.
Then put these questions to the centre:
- Is this an approved product, and is it approved in China for my condition? If it is a trial, what phase is it, and who is the sponsor?
- How many patients with my condition has this team treated with this product?
- Who manages side effects, and is intensive care on site?
- What does the estimate include, and what is excluded?
- What happens if the cells cannot be manufactured successfully?
- What records will I receive in English, and what follow-up do you expect?
Take them to your own specialist first. Our hospital profiles list centres that offer CAR-T.
General information, not medical or legal advice. Rules and prices change, so confirm anything that matters with the hospital or the relevant authority before you book.